Inhibitors of fatty acid uptake and methods of use

A method of inhibiting fatty acid uptake by cells, comprising:

• contacting said cells with a compound of Formula (II):
• or a pharmaceutically acceptable salt form thereof, wherein:
• R1 is H or NO2;
• R2 is selected from the group consisting of:
• H, F, Cl, Br, I, OH, and O(C1-6 alkyl);
• R3 is selected from the group consisting of:
• F, Cl, Br, I, OH, and O(C1-6 alkyl);
• and
• n is an integer from 0 to 5.

A method of inhibiting fatty acid uptake by cells, comprising:

• contacting said cells with a compound of Formula (III):
• or a pharmaceutically acceptable salt form thereof, wherein:
• R1 is H or O(C1-6 alkyl);
• and
• R2 is a substituted or unsubstituted heterocycloalkyl or heteroaryl.

A method of inhibiting fatty acid uptake by cells, comprising:

• contacting said cells with a compound of Formula (IV):
• or a pharmaceutically acceptable salt form thereof, wherein:
• R1 and R2 are independently selected from the group consisting of:
• H, F, Cl, Br, I, OH, and O(C1-6 alkyl).

A method of treating a disease, comprising:

• administering, to an individual, a compound of Formula (I):
• or a pharmaceutically acceptable salt form thereof, wherein:
• X is O or S;
• R1 is selected from the group consisting of:
• F, Cl, Br, I, OH, and O(C1-6 alkyl);
• R2, R3, and R4 are independently selected from the group consisting of:
• H, F, Cl, Br, I, OH, and O(C1-6 alkyl), wherein at least two of R2, R3, and R4 are not H.

A method of treating a disease, comprising:

• administering, to an individual, a compound of Formula (II):
• or a pharmaceutically acceptable salt form thereof, wherein:
• R1 is H or NO2;
• R2 is selected from the group consisting of:
• H, F, Cl, Br, I, OH, and O(C1-6 alkyl);
• R3 is selected from the group consisting of:
• F, Cl, Br, I, OH, and O(C1-6 alkyl);
• and
• n is an integer from 0 to 5.

A method of treating a disease, comprising:

• administering, to an individual, a compound of Formula (III):
• or a pharmaceutically acceptable salt form thereof, wherein:
• R1 is H or O(C1-6 alkyl);
• and
• R2 is a substituted or unsubstituted heterocycloalkyl or heteroaryl.

A method of treating a disease, comprising:

• administering, to an individual, a compound of Formula (IV):
• or a pharmaceutically acceptable salt form thereof, wherein:
• R1 and R2 are independently selected from the group consisting of:
• H, F, Cl, Br, I, OH, and O(C1-6 alkyl).